Comparative Trial of Serotonin Antagonists in the Management of MigraineBr Med J 1970; 2 doi: https://doi.org/10.1136/bmj.2.5705.327 (Published 09 May 1970) Cite this as: Br Med J 1970;2:327
- J. W. Lance,
- M. Anthony,
- B. Somerville
The effectiveness of five different serotonin antagonists in the prevention of migraine was compared in 290 patients followed for periods of up to three years. Methysergide 3-6 mg. daily was most effective, with 20% of treated patients becoming headache-free and a further 44% remaining more than “half improved.” The corresponding figures for BC105 were 10% and 40%, respectively.
The results with BC105 were significantly better than those with placebo (P<0·02). The total improvement rates with methdilazine (45%) and cyproheptadine (43%) were better than those with placebo (32%) but did not achieve statistical significance. A new preparation, methylergol carbamide maleate, which is chemically related to methysergide, did not give better results than placebo.